semaglutide safety How long do you stay on for weight loss Abstract 4134308: Re-evaluating the safety

The short half-life of native GLP- 1-based therapy in the circulation (approximately two minutes after intravenous administration and one to five hours after subcutaneous administration) posed a problem during its early development [9]

If youre pregnant or breastfeeding Regulatory bodies, including the MHRA, advise that GLP-1 medications should not be used during pregnancy or while breastfeeding

No documented evidence shows kidney damage from creatine in healthy individuals, and there is no known interaction between creatine and semaglutide that would increase kidney risk

This is a meaningful advantage over some injectable GLP-1 agonists, particularly exenatide, which is renally cleared and contraindicated in severe renal impairment

Zhang Y, Gu Y, Ren H, et al